Download the ebook to: Discover how proactive DMPK and toxicology strategies can de-risk your oncology pipeline and accelerate the path to IND submission. Learn how to integrate these critical functions into a unified preclinical development plan to avoid setbacks and strengthen your scientific narrative for regulatory bodies like… Read More
A new report from Cancer Research UK (CRUK) indicates that the UK immigration system is having a detrimental effect on research in the UK. CRUK’s institutes are led by and made up of a combination of UK and international researchers, but now it says that the UK… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
In the In Conversation With series, a part of the free DDW podcast and vodcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Nick Slack, Chairman and CEO of… Read More
In the In Conversation With series, a part of the free DDW podcast and vodcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Nick Slack, Chairman and CEO of… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
In this webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson is joined during the Q&A by Rachel Mendes, Senior… Read More
This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More
The tumour microenvironment (TME) is no longer considered a passive backdrop to cancer. It is a dynamic ecosystem that plays a central role in tumour growth, immune suppression, metastasis and treatment resistance. Whitepaper highlights: Understand how the TME drives cancer progression, immune evasion and therapeutic resistance Explore emerging strategies that… Read More
Download this technical note to learn: Streamlined Macrophage Workflow: Transform cryopreserved or PBMC-derived monocytes into M1 or M2 macrophages using a reproducible, high-throughput protocol. Comprehensive Validation: Confirm phenotype and function with live-cell imaging and phagocytosis assays for application-ready results. Accelerated Research: Enhance drug discovery, immunotoxicology, and screening workflows with both… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Thijs Spoor, CEO… Read More
One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding… Read More
Scientists have uncovered a protein that acts like a ‘suit of armour’ for cancer cells, shielding them from hostile environments and allowing one of the deadliest forms of skin cancer to spread through the body. A team of researchers from The Institute of Cancer Research, London, has identified that a… Read More
FUJIFILM Pharmaceuticals’ FF-10832—an investigational liposomal formulation of gemcitabine—has granted orphan drug designation for the treatment of biliary tract cancer (BTC) by the US Food and Drug Administration (FDA). FF-10832 is currently being evaluated in Phase IIa studies as monotherapy or in combination with pembrolizumab for the treatment of solid tumours… Read More
The European Commission has approved Tevimbra (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper… Read More
Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its third Innovation and Entrepreneurship Awards during an awards ceremony at Merchant Taylors’ Hall, London. Dr Alessia Errico, Associate Director of Search and Evaluation at Cancer Research Horizons, said: “These remarkable innovators demonstrate the determination and… Read More
